纳武利尤单抗联合维布妥昔单抗±苯达莫司汀治疗儿童、青少年及年轻成人复发/难治性霍奇金淋巴瘤
CheckMate 744是一项2期研究,纳入5-30岁复发/难治性经典型霍奇金淋巴瘤患者,采用风险分层、反应适应策略:纳武利尤单抗联合维布妥昔单抗诱导4周期,未达完全代谢缓解者接受维布妥昔单抗联合苯达莫司汀强化。标准风险队列44例中,诱导后完全代谢缓解率59%,巩固前任意时间达94%,1年无进展生存率91%,诱导期18%发生3/4级治疗相关不良事件。
要点
- 标准风险队列44例,诱导后完全代谢缓解率59%,巩固前任意时间达94%
- 1年无进展生存率91%
- 诱导期18%患者发生3/4级治疗相关不良事件
核心结论
- 风险分层、反应适应的挽救策略在儿童、青少年及年轻成人复发/难治性经典型霍奇金淋巴瘤中取得高完全代谢缓解率且毒性有限。
- 多数患者无需额外化疗(苯达莫司汀强化)。
- 需额外随访以确认疾病控制的持久性。
研究设计与样本
- CheckMate 744为2期研究,纳入5-30岁复发/难治性经典型霍奇金淋巴瘤患者。
- 风险分层主要基于复发时间、既往治疗及B症状是否存在。
- 本文报告标准风险队列的主要分析,低风险队列数据另行报告。
主要发现
- 44例患者接受治疗,中位年龄16岁。
- 最短随访15.6个月时,43例接受4周期诱导(1例中止),其中11例接受强化,32例进入巩固。
- 诱导后完全代谢缓解率为59%,巩固前任意时间(纳武利尤单抗联合维布妥昔单抗±维布妥昔单抗联合苯达莫司汀)为94%。
- 1年无进展生存率为91%。
- 诱导期间18%患者发生3/4级治疗相关不良事件。
关键数值与推荐
- 完全代谢缓解定义为Deauville评分≤3(Lugano 2014)。
- 诱导方案为纳武利尤单抗联合维布妥昔单抗4周期。
- 未达完全代谢缓解(Deauville评分>3)者接受维布妥昔单抗联合苯达莫司汀强化。
- 诱导或强化后达完全代谢缓解者按方案接受大剂量化疗/自体造血干细胞移植巩固。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需额外随访以确认疾病控制的持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with R/R cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was primarily based on time to relapse, prior treatment, and presence of B symptoms. We present the primary analysis of the standard-risk cohort. Data from the low-risk cohort are reported separately. Patients received 4 induction cycles with nivolumab plus BV; those without CMR (Deauville score >3, Lugano 2014) received BV plus bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol). Primary end point was CMR any time before consolidation. Forty-four patients were treated. Median age was 16 years. At a minimum follow-up of 15.6 months, 43 patients received 4 induction cycles (1 discontinued), 11 of whom received intensification; 32 proceeded to consolidation. CMR rate was 59% after induction with nivolumab plus BV and 94% any time before consolidation (nivolumab plus BV ± BV plus bendamustine). One-year progression-free survival rate was 91%. During induction, 18% of patients experienced grade 3/4 treatment-related adverse events. This risk-stratified, response-adapted salvage strategy had high CMR rates with limited toxicities in CAYA with R/R cHL. Most patients did not require additional chemotherapy (bendamustine intensification). Additional follow-up is needed to confirm durability of disease control. This trial was registered at www.clinicaltrials.gov as #NCT02927769.
引用
- Harker-Murray P, Mauz-Körholz C, Leblanc T, et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023. PMID: 36564047. doi:10.1182/blood.2022017118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。